Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships [Yahoo! Finance]
Lunai Bioworks Inc. (LNAI)
Company Research
Source: Yahoo! Finance
Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies. SACRAMENTO, Calif., and HOUSTON April 15, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and patient engagement company, today announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI) with Geneial to pursue a strategic collaboration in rare neurological disorders. Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.) The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Rare diseases affect approximately 300 million people globally, yet drug developme
Show less
Read more
Impact Snapshot
Event Time:
LNAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LNAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LNAI alerts
High impacting Lunai Bioworks Inc. news events
Weekly update
A roundup of the hottest topics
LNAI
News
- Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsPR Newswire
- Lunai Bioworks (LNAI) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionPR Newswire
- BC-Most Active Stocks [Yahoo! Finance]Yahoo! Finance
- Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery ApplicationsPR Newswire
LNAI
Sec Filings
- 4/15/26 - Form DEFR14A
- 4/13/26 - Form DEF
- 4/2/26 - Form PRE
- LNAI's page on the SEC website